An AmeriHealth Caritas Clinical Policy, dated 1 September, 2018, has been issued for the exclusive coverage of the coflex interlaminar stabilisation device (Paradigm Spine) for the treatment of lumbar spinal stenosis.
Lumbar spinal stenosis (LSS) affects 1.6 million patients annually and is often associated with significant leg and back pain, leg numbness and weakness, causing a significant reduction in an active lifestyle.
Traditional surgical treatment options for LSS include a decompression that removes bone and soft tissue and may also require a fusion to stabilise the spine. The coflex device is a non-fusion, motion-preserving stabilisation implant that is FDA PMA approved for the treatment of lumbar spinal stenosis and is used in conjunction with a decompression, or used in lieu of a spinal fusion.
Marc Viscogliosi, Paradigm Spine chairman & CEO, commented, “With this continued payor coverage momentum, we look forward to further expanding access to our coflex solution, which is backed by more than 90 peer-reviewed published articles, including landmark long-term follow-up clinical studies, and spine medical society guidelines.”
